



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Thursday, August 21, 2008

Northfield Laboratories

[View the current Northfield Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/5434-Northfield+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/5434-Northfield+Laboratories.html>)

Contact Details:

1560 Sherman Avenue

Evanston

IL

60201-4800

United States of America

Tel: 847 864 3500

Fax:

Email: investor_relations@northfieldlabs.com

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. Northfield's product, PolyHeme®, is a human hemoglobin-based temporary oxygen-carrying red blood cell substitute. PolyHeme® simultaneously restores lost blood volume and hemoglobin levels and is designed for rapid, massive infusion. PolyHeme® requires no cross-matching. It is compatible with all blood types and therefore immediately available for infusion. It has an extended shelf life in excess of 12 months. PolyHeme® has been rapidly infused in trauma patients during urgent life-threatening blood loss in sufficiently large quantities to be considered well-tolerated in this patient population. Patient enrollment is now complete in a landmark Phase III, randomized, controlled open-label, multicenter, parallel group study to evaluate the safety and efficacy of PolyHeme® when used to treat severely injured patients in hemorrhagic shock before they reach a hospital. Under the protocol, treatment began at the scene of the injury or in the ambulance, and continued during transport and a 12 hour post-injury period in the hospital. The use of PolyHeme® in this setting has the potential to address a critical, unmet medical need. The study is based on two potential life-saving benefits. The first is starting infusion of an oxygen-carrying fluid at the scene of injury and continuing during transport to the hospital. Because blood is not routinely carried in ambulances, PolyHeme® represents a potential improvement over the current standard of care. The second opportunity is the potential to improve the outcome associated with the use of donated blood in the early hospital period in critically injured patients. Although blood is the current standard of care, there is a growing body of scientific evidence pointing to the adverse immunomodulatory effects of early blood transfusion in trauma patients, specifically the incidence of multiple organ failure and the resultant associated mortality. There are also published data indicating that these same effects may not occur with PolyHeme®. Thus while blood is available in the hospital, PolyHeme® is being evaluated as a potential better alternative for the early care of the injured patient.

Recent Publications by Northfield Laboratories:



- [The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable.](#)
BACKGROUND: Human polymerized hemoglobin (PolyHeme, Northfield...4th December, 2002 Northfield Laboratories Inc., Evanston, IL, USA.- J Am Coll Surg. 2002 Oct;195(4):445-52; discussion 452-5.

BioNews Results for Northfield Laboratories



- [Northfield Laboratories Inc. Reports Fiscal 2008 Fourth Quarter and Year-End Financial Results](#)
Yahoo!: Aug 15 2008 12:23AM Matching: northfield laboratories
- [Northfield Laboratories Inc. Reports Fiscal 2008 Fourth Quarter and Year-End Financial Results](#)
Genetic Engineering News: Aug 14 2008 9:56PM Matching: northfield laboratories
- [Northfield Laboratories Inc. Announces Annual Meeting Date; Outlines Proposals Requiring Shareholder Approval](#)
Genetic Engineering News: Aug 3 2008 9:28AM Matching: northfield laboratories
- [Northfield Laboratories Inc. Announces Annual Meeting Date; Outlines Proposals Requiring Shareholder Approval](#)
DiGiTAL50: Aug 2 2008 10:04AM Matching: northfield laboratories
- [Northfield Laboratories Inc. Announces Annual Meeting Date; Outlines Proposals Requiring Shareholder Approval](#)
Genetic Engineering News: Aug 1 2008 11:03PM Matching: northfield laboratories

Northfield Laboratories Patents:



- 7291592- [Method for treating patients with massive blood loss](#)
- 5061688- [Hemoglobin multiple emulsion](#)
- 5194590- [Acellular red blood cell substitute](#)
- 5217648- [Process for preparation of hemoglobin multiple emulsions](#)
- 5438041- [Oxygen carrying multiple emulsions](#)
- 5464814- [Acellular red blood cell substitute](#)
- 6133425- [Acellular red blood cell substitute](#)
- 6202546- [Liquid colostrum for dairy products](#)
- 6248366- [Liquid colostrum for dairy products](#)

- 6323320- [Acellular red blood cell substitute](#)
- 6498141- [Method and apparatus for preparing an acellular red blood cell substitute](#)
- 6552173- [Acellular red blood cell substitute](#)
- 6914127- [Acellular red blood cell substitute](#)
- 7135553- [Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing](#)
- 7202341- [Stabilized hemoglobin solutions](#)
- 4826811- [Acellular red blood cell substitute](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

